NCT06906367 - A Study of Patients With Fabry Disease (US Specific) | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

June 30, 2032

Study Completion Date

June 30, 2032

Conditions

Fabry Disease

Interventions

DRUG

migalastat HCl

Non-interventional study of participants receiving migalastat HCl 150 mg

DRUG

ERT

Non-interventional study of participants receiving enzyme replacement therapy

Trial Locations (4)

Lysosomal and Rare Disorders Research and Treatment Center, Inc., Fairfax

Emory Genetics, Atlanta

Washington University School of Medicine, St Louis

Renal Disease Research Institute, Dallas